Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease

Trial Profile

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Duloxetine (Primary) ; Apomorphine; Levodopa
  • Indications Neurological disorders; Parkinson's disease
  • Focus Pharmacodynamics
  • Acronyms DOULOX
  • Most Recent Events

    • 21 Feb 2017 Status changed from recruiting to completed.
    • 10 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 09 Dec 2013 Planned end date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top